When: Close $335-340 + bullish reversal candle + volume >7M + MACD histogram turning

Then: Add 25% of target

When: Close above $356.80 + volume >7M + positive MACD histogram cross

Then: Add 25% of target

When: Post-Sep 16 FOMC + Q3 earnings validates NII ≥$25.5B + contained credit

Then: Reserve for future deployment

HOLD current position sizing; do not add at $353.51; first add zone $335-340 with confirmation; trim into $360-366 rallies; cut exposure immediately if $348 breaks on volume

• NII sequential growth decelerating Q1 to Q2; interest expense grew $23.97B to $25.1B indicating real spread compression
• MACD bearish cross confirmed with histogram negative 0.82 and widening; 200 SMA at $316.61 means stock is 11.6% above long-term mean signaling mean reversion risk
• Critical technical support cluster: 50 SMA at $350.15, lower Bollinger band at $349.93, late July swing low at $344.71
• Valuation premium: P/B of 2.66 vs sector 1.2-1.5, P/Tangible book ~3.25 vs 1.5-2.0, Forward P/E of 14.13 against slowing EPS growth
• Q2 EPS of 47% was inflated by $4.39B special charges; normalized net income ~$17.8B vs headline $21.16B
• CEO succession is largest unaddressed governance variable; any succession news would compress multiples
• September 16 FOMC at 55% probability risks duration damage on ~$600B AFS book while deposit betas lag and reset higher over next two quarters
• Anthropic IPO rumored lead bookrunners are Goldman and Morgan Stanley; JPM role is pure speculation not a thesis catalyst
• $65B IG issuance wave could price wider in stagflationary setup with widening spreads; aggressive case only counts gross wallet ignoring underwriting risk capital
• JPM $1.52T loan book faces credit normalization risk from oil shock above $100; buybacks are discretionary and historically suspended at worst moments
• ATR of $5.92 makes proposed $348 stop (only ~$5.51 below entry) less than one ATR with ~50% probability of weekly stop-out in choppy regime
• 4-to-1 reward-to-risk on proposed aggressive trade is negative expected value given elevated stop-out probability during catalyst-dense September window

→ vs aggressive: NII 0.6% sequential growth is not a win—it's a deceleration signal on a $25B base where $150M incremental contribution is trailing momentum from prior quarters

→ vs aggressive: MACD bullish cross thesis is flawed—a confirmed bearish cross with histogram at negative 0.82 and widening is not a one-day print but momentum deterioration building over time

→ vs aggressive: 200 SMA at $316.61 is not a floor to buy dips; it's a trailing indicator that will be far below price when the next leg down starts, and 11.6% above mean is a mean reversion setup

→ vs aggressive: Quality premium argument ignores that P/B of 2.66 vs sector 1.2-1.5 is a cyclical peak valuation, not a structural one, and the 47% EPS was inflated by $4.39B special charges

→ vs aggressive: Jamie Premium dismissal is wrong—succession at a $940B franchise is the single largest unaddressed governance variable, not a soft thematic risk

→ vs aggressive: FOMC catalyst thesis is incomplete—celebrating front-end rate lift ignores duration damage on ~$600B AFS book if long end spikes on hawkish surprise plus $119B Treasury supply plus $65B IG supply

→ vs aggressive: Anthropic IPO role is pure speculation—Goldman and Morgan Stanley are rumored bookrunners; JPM co-manager role would add ~0.05% of market cap in fees, not a catalyst

→ vs aggressive: Buyback floor argument ignores that $1.52T loan book provisioning will force management to dial down buybacks when credit conditions deteriorate in late-cycle

→ vs aggressive: Proposed trade of 50% size add at $353.51 with $348 stop has negative expected value—the stop is less than one ATR (~5.92) giving ~50% weekly probability of stop-out in choppy regime entering catalyst-dense September window

HOLD current position; trim 15-20% into rallies to $360-$366; add on upside trigger ($356.80 reclaim with positive MACD) or downside trigger ($335-$340); widen stop to $344

• 17.79% ROE versus 10-12% peer median justifies structural premium, but tactical risk premium into September 16 FOMC is real for different reasons
• $5.51 stop on a $5.92 ATR stock is operationally reckless into a known catalyst window
• Anthropic IPO optionality is unconfirmed and rounding error on $940B market cap—treating it as near-term catalyst is narrative capture
• Stripping out $4.39B in one-time charges normalizes Q2 net income to ~$17.8B versus $21.16B headline; 47% EPS growth is marketing, not run-rate
• $600B AFS securities portfolio creates asymmetric duration risk to the downside on hawkish surprise
• 200 SMA at $316.61 grinding higher all year; price 11.6% above a rising average is trend confirmation, not a warning
• JPM maintained buyback cadence through 2023 regional bank stress and early hiking cycle—treating buyback floor as fragile contradicts observed behavior
• $335-$340 pullback target requires fundamental deterioration, not technical wobble; buyback program mathematically prevents that pullback
• Hold is correct because MACD is confirmed bearish with widening histogram, price near lower Bollinger band ($349.93), and 55% probability of hawkish surprise 8 days from FOMC
• Neutral synthesis: reduce exposure ahead of one tail, prepare to add on confirmation, avoid binary framing that conflates structural quality with tactical entry

→ vs aggressive: $5.51 stop on $5.92 ATR is coin flip with tail risk, not 4:1 reward-to-risk; conflates structural premium (valid) with tactical entry (unfavorable); Anthropic IPO optionality is unconfirmed rounding error, not near-term catalyst

→ vs conservative: 11.6% above rising 200 SMA is bullish confirmation, not bearish warning; JPM buyback discipline contradicts treating buyback floor as fragile; waiting for $335-$340 may mean missing the move as buybacks prevent the pullback